Treatment of Penile Cancer with Fixed Inguinal Nodal Mass or Pelvic Lymphadenopathy (cN3)

This page addresses the management of penile squamous cell carcinoma presenting with a fixed inguinal nodal mass or pelvic lymphadenopathy (cN3) in patients who are fit for cisplatin-based chemotherapy — a high-risk staging category requiring a structured multimodal approach.

Clinical Scenario

cN3 disease is characterised by a fixed inguinal nodal mass or pelvic lymph node involvement (unilateral or bilateral). In cisplatin-eligible patients presenting at this stage, guidelines favour neoadjuvant chemotherapy using a cisplatin- and taxane-based combination over upfront surgery, reserving surgical intervention for a subsequent consolidative step.

Treatment Approach (Partial Overview)

For patients who respond to neoadjuvant chemotherapy — or who show no evidence of progression — consolidative surgical resection of all residual disease is the preferred next step, carried out at a defined interval after chemotherapy completion to allow haematologic recovery. The full selection criteria, surgical approach, and sequencing algorithm are contained in the structured protocol.

Complete regimen details available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

View source ↗